Tuesday, March 25, 2008 1:58:03 PM
...
Christine A. Tsingos, Chief Financial Officer, Vice President
Today we will review the fourth quarter and full-year financial results for 2007, the impact of our DiaMed acquisition, as well as provide some insight into our thinking for 2008. We know this is a lot of information and I’ll do my best to walk through it slowly.
Let’s start with a review of the quarterly results. Net sales for the fourth quarter of fiscal 2007 were $459.7 million, an increase of more than 28% versus the year-ago period sales of $343.1 million. These quarterly sales include approximately $62 million contributed by the DiaMed business.
Excluding DiaMed, sales in the fourth quarter grew 16% compared to last year, to $397.7 million. On an organic, currency-neutral basis, sales for the quarter grew 9%. This strong year-over-year growth was fueled by solid performance in both Life Sciences and Clinical Diagnostics.
During the quarter we posted record sales with in our Life Sciences group. This growth was the result of increased sales of Protein Expression, amplification and processed chromatography products. Diagnostics also posted a record quarter even before the inclusion of DiaMed which is a reflection of strong performance in blood virus, clinical systems and quality control.
Consolidated gross margin for the quarter was a reported 50.8% which includes more then $3 million of amortization expense related to the DiaMed transaction and another $3 million of foregone profit margin as required under purchase accounting. The gross margin for the base Bio-Rad business came in as expected at 53.4% as product mix in our fourth quarter typically shifts toward lower margin instrument sales.
SG&A expense for the fourth quarter was $163 million or 35.5% of sales. This represents a significant increase from just last quarter but it is important to note that the inclusion of DiaMed in our consolidated results constitutes more than $20 million of that increase. In addition approximately $2 million of amortization expense related to the deal, $8 million of negative foreign currency affect and increased selling costs, commissions and bonuses associated with the strong top-line growth also contributed to this sequential rise...(cont'd)
http://seekingalpha.com/article/68934-bio-rad-laboratories-inc-q4-2007-earnings-call-transcript?source=yahoo
Recent BIO News
- Dell, Palantir, and Erie Will Be Added to the S&P 500; Boeing Avoids Strike; Apple Event Takes Place Today • IH Market News • 09/09/2024 10:05:35 AM
- Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 • PR Newswire (US) • 09/06/2024 10:43:00 PM
- Bio-Rad’s Management to Participate in Fireside Chat During Wells Fargo’s 2024 Healthcare Conference • Business Wire • 08/22/2024 08:30:00 PM
- Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer • Business Wire • 08/20/2024 12:30:00 PM
- Bio-Rad Reports Second-Quarter 2024 Financial Results • Business Wire • 08/01/2024 08:15:00 PM
- Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024 • Business Wire • 07/17/2024 08:30:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 10:37:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 05:42:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/13/2024 09:50:32 PM
- Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group • Business Wire • 05/30/2024 01:00:00 PM
- Bio-Rad’s Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference • Business Wire • 05/23/2024 08:15:00 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/09/2024 08:30:20 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/08/2024 08:38:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:31:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:18:26 PM
- Bio-Rad Reports First-Quarter 2024 Financial Results • Business Wire • 05/07/2024 08:15:00 PM
- Bio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference • Business Wire • 05/01/2024 01:00:00 PM
- Bio-Rad Announces Life Science Group Management Changes • Business Wire • 04/26/2024 12:30:00 PM
- Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 • Business Wire • 04/18/2024 01:00:00 PM
- Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay • GlobeNewswire Inc. • 04/11/2024 09:30:00 PM
- Bio-Rad’s Chief Operating Officer Andrew Last to Retire • Business Wire • 04/10/2024 08:15:00 PM
- Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer • Business Wire • 03/20/2024 12:30:00 PM
- Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day • Business Wire • 02/22/2024 09:30:00 PM
- Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results • Business Wire • 02/15/2024 09:15:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM